BioCentury | Jun 23, 2020
Distillery Therapeutics

Blocking cGAS signaling for alcohol-related liver disease

DISEASE CATEGORY: Hepatic INDICATION: Liver disease Targeting the cGAS-IRF3 signaling pathway by inhibiting cGAS or the gap junction protein GJB1 could treat alcohol-related liver disease. In liver samples from alcoholic-related liver disease patients, high cGAS...
BC Innovations | Apr 7, 2016
Distillery Therapeutics

Therapeutics: Gap junction protein β1, 32kDa (GJB1; CX32; connexin-32)

Neurology INDICATION: Neuropathy Mouse studies suggest GJB1 could help treat Charcot-Marie-Tooth type 1X (CMT1X), a disease caused by GJB1 mutations. In a GJB1-knockout mouse model of CMT1X, intrathecal injection of a viral vector encoding GJB1...
BC Innovations | Feb 2, 2012
Distillery Therapeutics

Indication: Hepatic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Drug-induced liver toxicity (DILI) Gap junction protein b1, 32 kDa (GJB1; CX32; connexin-32) Mouse studies identified a small molecule inhibitor of CX32 that could...
BC Innovations | Feb 2, 2012
Distillery Therapeutics

Indication

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Bladder cancer Keratin 14 (KRT14) Patient sample studies suggest KRT14 could help predict bladder cancer prognosis. In two sets of gene and protein expression data...
BC Innovations | Feb 2, 2012
Targets & Mechanisms

Closing the gap on liver toxicity

U.S. researchers have identified a small molecule gap junction inhibitor that protects mice from drug-induced liver toxicity. 1 The team has founded Heprotech Inc. to further characterize and optimize the inhibitor. Gap junctions are multiprotein...
Items per page:
1 - 5 of 5